Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.32 is 17% below its 4-year average of 0.38, near the low end of its 4-year range (-0.77–56.90).
As of the fiscal period ended Tuesday, June 30, 2026. 97.78% below its 12-month average of 14.22.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.32.
DEBT TO EQUITY RATIO
0.32
DEBT TO EQUITY RATIO AVG TTM
14.22
DEBT TO EQUITY RATIO AVG 3Y
0.87
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-97.78%
CURRENT VS 3Y AVG
-63.62%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 740 covered companies
CURRENT VS SECTOR MEDIAN
+186.69%
vs the sector median at left
FibroBiologics, Inc. Common Stock
Market Cap
$2.52M
Debt to Equity Ratio
0.32
TTM Avg
14.22
3Y Avg
0.87
5Y Avg
N/A
Market Cap
$2.55M
Debt to Equity Ratio
0.38
TTM Avg
0.37
3Y Avg
0.27
5Y Avg
0.27
Market Cap
$2.48M
Debt to Equity Ratio
2.52
TTM Avg
6.25
3Y Avg
5.01
5Y Avg
3.33
Market Cap
$2.40M
Debt to Equity Ratio
0.03
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$2.33M
Debt to Equity Ratio
0.01
TTM Avg
0.88
3Y Avg
0.53
5Y Avg
0.53
Market Cap
$2.32M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $2.52M | 0.32 | 14.22 | 0.87 | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | 0.38 | 0.37 | 0.27 | 0.27 |
| Jaguar Health, Inc. (JAGX)vs › | $2.48M | 2.52 | 6.25 | 5.01 | 3.33 |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | N/A | 0.11 | 0.13 | 0.10 |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.40M | 0.03 | 0.05 | 0.03 | 0.02 |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 0.01 | 0.49 | 0.33 | 0.20 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.33M | 0.01 | 0.88 | 0.53 | 0.53 |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| iSpecimen Inc. (ISPC)vs › | $2.72M | 0.14 | 0.09 | 0.05 | 0.06 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.07M | 0.18 | 0.11 | 0.06 | 0.04 |
Debt/Equity
0.32
Current Ratio
2.64
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.32 |
| 2026-03-31 | 0.95 |
| 2025-12-31 | 0.39 |
| 2025-09-30 | 56.90 |
| 2025-06-30 | 12.53 |
| 2025-03-31 | 3.03 |
| 2024-12-31 | 3.86 |
| 2024-09-30 | 0.57 |
| 2024-06-30 | -0.77 |
| 2024-03-31 | -0.55 |
| 2023-12-31 | 1.39 |
| 2023-09-30 | 0.17 |
| 2023-06-30 | 0.17 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
